108. Evaluation of the Impact of Dalbavancin Usage on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital
Sign Up to like & getrecommendations! Published in 2021 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofab466.310
Abstract: Abstract Background Dalbavancin is a long-acting second-generation lipoglycopeptide antibiotic with potent activity against Gram-positive organisms. Dalbavancin is currently FDA approved for acute bacterial skin and soft tissue infections (ABSSTIs). Growing evidence suggests that patients can… read more here.
Keywords: 108 evaluation; impact dalbavancin; cost savings; hospital ... See more keywords